Table 2.
Association between various factors and overall survival (OS)
| Factors | OS | p-value | |||
|---|---|---|---|---|---|
| < 6 months (n = 14) | 6 months–1 year (n = 28) | 1 year–2 years (n = 14) | > 2 years (n = 4) | ||
| Age | |||||
| < 39 years | 8 (22.2) | 19 (52.8) | 6 (16.7) | 3 (8.3) | 0.414 |
| > 40 years | 6 (25) | 9 (37.5) | 8 (33.3) | 1 (4.2) | |
| Gender | |||||
| Male | 9 (24.3) | 15 (40.5) | 11 (29.7) | 2 (5.4) | 0.434 |
| Female | 5 (21.7) | 13 (56.5) | 3 (13) | 2 (8.7) | |
| Duration of symptoms | |||||
| < 6 months | 13 (23.2) | 26 (46.4) | 13 (23.2) | 4 (7.1) | 0.959 |
| > 6 months | 1 (25) | 2 (50) | 1 (25) | 0 (0) | |
| ECOG performance status | |||||
| ECOG 1 | 2 (15.4) | 6 (46.2) | 5 (38.5) | 0 | 0.671 |
| ECOG 2 | 9 (27.3) | 14 (42.4) | 7 (21.2) | 3 (9.1) | |
| ECOG 3 | 3 (21.4) | 8 (57.1) | 2 (14.3) | 1 (7.1) | |
| Lesion | |||||
| Single | 14 (25.5) | 23 (41.8) | 14 (25.5) | 4 (7.3) | 0.101 |
| Multiple | 0 (0) | 5 (100) | 0 (0) | 0 (0) | |
| Tumour size | |||||
| < 4 cm | 6 (24) | 9 (36) | 6 (24) | 4 (16) | 0.084 |
| > 4 cm | 8 (22.9) | 19 (54.3) | 8 (22.9) | 0 (0) | |
| Per op | |||||
| Gross total resection | 2 (10.5) | 12 (63.2) | 2 (10.5) | 3 (15.8) | 0.030* |
| > 50% removal | 6 (21.4) | 12 (42.9) | 10 (35.7) | 0 (0) | |
| Only biopsy taken | 6 (46.2) | 4 (30.8) | 2 (15.4) | 1 (7.7) | |
| Post-op MRI | |||||
| No residual | 1 (5.3) | 10 (52.6) | 6 (31.6) | 2 (10.5) | 0.137 |
| Residual | 13 (31.7) | 18 (43.9) | 8 (19.5) | 2 (4.9) | |
| IDH | |||||
| Mutant | 0 (0) | 1 (100) | 0 (0) | 0 (0) | 0.915 |
| Wild | 1 (16.7) | 3 (50) | 2 (33.3) | 0 (0) | |
| Not known | 13 (24.5) | 24 (45.3) | 12 (22.6) | 4 (7.5) | |
| Radiotherapy started | |||||
| < 6 weeks | 14 (23.7) | 27 (45.8) | 14 (23.7) | 4 (6.8) | 0.762 |
| > 6 weeks | 0 (0) | 1 (100) | 0 (0) | 0 (0) | |
| Completed radiotherapy | |||||
| Yes | 10 (20) | 23 (46) | 14 (28) | 3 (6) | 0.216 |
| No | 4 (40) | 5 (50) | 0 (0) | 1 (10) | |
| Adjuvant temozolomide for 6 months | |||||
| Yes | 3 (8.1) | 20 (54.1) | 10 (27) | 4 (10.8) | 0.003* |
| No | 11 (47.8) | 8 (34.8) | 4 (17.4) | 0 (0) | |
| Brain volume | |||||
| Mean | 1333 ± 143.92 | 1297.82 ± 132.92 | 1346.57 ± 123.73 | 1278.75 ± 34.06 | 0.600 |
| PTV volume | |||||
| Mean | 305.71 ± 99.41 | 344.39 ± 274.19 | 354.29 ± 137.91 | 309.25 ± 111.93 | 0.508 |
| Treated % brain volume (%) | |||||
| Mean | 23.19 ± 7.89 | 26.65 ± 22.08 | 27.05 ± 12.35 | 24.12 ± 8.36 | 0.634 |
| Recurrent site | |||||
| Yes | 1 (4.2) | 10 (41.7) | 9 (37.5) | 4 (16.7) | 0.001* |
| No | 13 (36.1) | 18 (50) | 5 (13.9) | 0 (0) | |
| Site | |||||
| In field | 1 (8.3) | 3 (25) | 5 (41.7) | 3 (25) | 0.294 |
| Out Field | 0 (0) | 7 (58.3) | 4 (33.3) | 1 (8.3) | |
| Disease-free survival | |||||
| < 6 months | 14 (29.8) | 26 (55.3) | 7 (14.9) | 0 (0) | < 0.001* |
| 6 months–1 year | 0 (0) | 2 (22.2) | 7 (77.8) | 0 (0) | |
| > 1 year | 0 (0) | 0 (0) | 0 (0) | 4 (100) | |
ECOG — Eastern Cooperative Oncology Group; MRI — magnetic resonance imaging; IDH — isocitrate dehydrogenase; PTV — planning target volume
The table shows the factors which effects the OS. The study shows adjuvant temozolomide (p = 0.003*) and gross total resection (p = 0.030*) are statistically significant for OS